RWJ Health Connect | Patient PortalGo
  • 1-888-MD-RWJUH
  • YouTube

Lung Cancer Trials

Study Number

PI

Type

Stage

Title

S1400

Dr. Young

Second Line

Stage IV or recurrent

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

A151216
ALCHEMIST

Dr. Young

Adjuvant

IB(>4cm) to III A

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081105

Dr. Young

Adjuvant EGFR mutant

IB(>4cm) to III A

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

E4512

Dr. Young

Adjuvant
ALK mutation

IB(>4cm) to III A

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EA5142

Dr. Young

Adjuvant PDL1 testing

IB(>4cm) to III A

A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers(NSCLC) - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)

LUNG Care

Dr. Caccavale

Registry

Stage IA or IB

LUNG Cancer Registry: An Open Registry to
Measure the Impact of Adding RNA Expression
Testing (myPlan Lung Cancer) on Referral Decisions
in Newly Diagnosed Early Stage Lung adenocarcinoma
Patients

RTOG 1306

Dr. Dobrescu

Adjuvant Lung

Unresectable Stage IIIA-B NSCLC (non squamous)

A Randomized Phase III Trial of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer

For more information, please call 

Siby Varughese, RN, MA, Research Manager at (908) 685-2481